<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">AMINOCAPROIC ACID <img border="0" src="../images/pr.gif"/></span><br/>(a-mee-noe-ka-proe'ik)<br/><span class="topboxtradename">Amicar, </span><span class="topboxtradename"> EACA (epsilon-aminocaproic acid)<br/></span><b>Classifications:</b> <span class="classification">blood formers, coagulators, and anticoagulants</span>; <span class="classification">hemostatic</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mg/mL injection; 500 mg tablets; 250 mg/mL syrup</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic hemostatic with specific antifibrinolysis action. Acts principally by inhibiting plasminogen activator substance;
         to a lesser degree slightly inhibits activity of plasmin (fibrinolysin), which is concerned with destruction of clots. Does
         not control bleeding caused by loss of vascular integrity.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Acts as an inhibitor of fibrinolytic bleeding.</p>
<h1><a name="uses">Uses</a></h1>
<p>To control excessive bleeding resulting from systemic hyperfibrinolysis, a pathologic condition that may accompany heart surgery,
         portocaval shunt, abruptio placentae, aplastic anemia, and carcinoma of lung, prostate, cervix, and stomach. Also used in
         urinary fibrinolysis associated with severe trauma, anoxia, shock, urologic surgery, and neoplastic diseases of GU tract.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>To prevent hemorrhage in hemophiliacs undergoing dental extraction; as a specific antidote for streptokinase or urokinase
         toxicity; to prevent recurrence of subarachnoid hemorrhage, especially when surgery is delayed; for management of amegakaryocytic
         thrombocytopenia; and to prevent or abort hereditary angioedema episodes.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Severe renal impairment; active disseminated intravascular clotting (DIC); upper urinary tract bleeding (hematuria); hemophilia;
         benzyl alcohol hypersensitivity, especially in neonates; paraban hypersensitivity; pregnancy (category C), lactation. Safety
         and efficacy in children have not been established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Cardiac, renal, or hepatic disease; renal impairment; history of pulmonary embolus or other thrombotic diseases; hypovolemia.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hemostatic</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO/IV</span> 45 g during first hour, then 11.25 g qh for 8 h or until bleeding is controlled (max: 30 g/24h)<br/><span class="rdage">Child:</span> <span class="rdroute">PO/IV</span> 100 mg/kg during first hour, then 33.3 mg/kg qh (max: 18 g/m<sup>2</sup>/24 h)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>
            				Note: May need to give patient as many as 10 tablets or 4 tsp for a 5 g dose during the first hour of treatment (each tablet contains
            500 mg, syrup contains 250 mg/mL).
            			
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> Dilute parenteral aminocaproic acid before use. Each 4 mL (1 g) is diluted with 50 mL of NS, D5W, or RL.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> IV Infusion:</span>   Physician orders specific IV flow rate. Usual rate is 5 g or a fraction thereof over first hour (5 g/250 mL). Give each additional gram over 1 h. Avoid rapid infusion to prevent hypotension, faintness, and bradycardia or other arrhythmias. 
               </p>
</td>
</tr>
</table>
<ul>
<li>Store in tightly closed containers at 15°30° C (59°86° F) unless otherwise directed. Avoid
            freezing.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Dizziness, malaise, headache, seizures. <span class="typehead">CV:</span> Faintness, orthostatic hypotension; dysrhythmias; thrombophlebitis, thromboses. <span class="typehead">Special Senses:</span> Tinnitus, nasal congestion. Conjunctival erythema. <span class="typehead">GI:</span> Nausea, vomiting, cramps, diarrhea, anorexia. <span class="typehead">Urogenital:</span> Diuresis, dysuria, urinary frequency, oliguria, reddish-brown urine (myoglobinuria), <span class="speceff-life">acute renal failure</span>. Prolonged menstruation with cramping. <span class="typehead">Skin:</span> Rash. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>
<span class="alt">Serum potassium</span> may be elevated (especially in patients with impaired renal function).
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">estrogens</span>, <span class="classification">oral contraceptives</span> may cause hypercoagulation. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract. <span class="typehead">Peak:</span> 2 h. <span class="typehead">Distribution:</span> Readily penetrates RBCs and other body cells. <span class="typehead">Elimination:</span> 80% excreted as unmetabolized drug in 12 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Check IV site at frequent intervals for extravasation.</li>
<li>Observe for signs of thrombophlebitis. Change site immediately if extravasation or thrombophlebitis occurs (see Appendix F).</li>
<li>Monitor &amp; report S&amp;S of myopathy: muscle weakness, myalgia, diaphoresis, fever, reddish-brown urine (myoglobinuria), oliguria,
            as well as thrombotic complications: arm or leg pain, tenderness or swelling, Homan's sign, prominence of superficial veins,
            chest pain, breathlessness, dyspnea. Drug should be discontinued promptly.
         </li>
<li>Monitor vital signs and urine output.</li>
<li>Lab tests: with prolonged therapy, monitor creatine phosphokinase activity and urinalyses for early detection of myopathy.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report difficulty urinating or reddish-brown urine.</li>
<li>Report arm or leg pain, chest pain, or difficulty breathing.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>